NAVIDEA BIOPHARMACEUTICALS I (NAVBQ)
Institutional ownership reported to the SEC as of Q1 2024, across 21 quarters.
1
Reporting holders
$13
Reported value
0.0%
Held as options
-3
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| Parallel Advisors, LLC | $13 | 350 | 0.00% | 6q | HELD |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q1 2024 | 1 | $13 | 350 | 0 | 0 | 0 | 0.0% |
| Q4 2023 | 4 | $469 | 11,240 | 2 | 0 | 0 | 0.0% |
| Q3 2023 | 23 | $195.8K | 2,182,566 | 3 | 5 | 2 | 0.0% |
| Q2 2023 | 23 | $138.5K | 1,505,823 | 6 | 6 | 3 | 0.0% |
| Q1 2023 | 23 | $252.4K | 984,356 | 2 | 1 | 8 | 0.3% |
| Q4 2022 | 21 | $286.5K | 1,370,784 | 10 | 2 | 1 | 0.8% |
| Q3 2022 | 19 | $448.6K | 1,512,899 | 3 | 4 | 5 | 14.7% |
| Q2 2022 | 19 | $1.4M | 1,500,011 | 3 | 4 | 4 | 20.1% |
| Q1 2022 | 19 | $1.5M | 1,512,944 | 0 | 1 | 9 | 21.7% |
| Q4 2021 | 26 | $2.2M | 1,680,818 | 2 | 6 | 5 | 22.8% |
| Q3 2021 | 28 | $3.6M | 1,574,993 | 3 | 3 | 8 | 24.0% |
| Q2 2021 | 25 | $4.0M | 1,683,212 | 3 | 8 | 5 | 23.6% |
| Q1 2021 | 30 | $4.5M | 1,869,685 | 2 | 11 | 4 | 16.7% |
| Q4 2020 | 30 | $4.4M | 1,593,774 | 0 | 5 | 10 | 23.0% |
| Q3 2020 | 35 | $5.1M | 1,606,082 | 4 | 8 | 11 | 15.1% |
| Q2 2020 | 34 | $6.5M | 1,527,369 | 14 | 10 | 3 | 6.9% |
| Q1 2020 | 24 | $781.0K | 923,869 | 3 | 1 | 4 | 9.7% |
| Q4 2019 | 22 | $946.5K | 548,387 | 4 | 6 | 0 | 27.0% |
| Q3 2019 | 25 | $440.0K | 547,625 | 7 | 5 | 3 | 13.9% |
| Q2 2019 | 23 | $406.0K | 627,237 | 24 | 0 | 0 | 3.4% |
| Q1 2019 | 2 | $8.0K | 63,294 | 2 | 0 | 0 | 0.0% |